<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796950</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1-16-02-261-16</org_study_id>
    <nct_id>NCT02796950</nct_id>
  </id_info>
  <brief_title>The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion</brief_title>
  <official_title>The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine
      stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in
      the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1
      are increased in response to acipimox. The hypothesis is that G protein coupled receptors on
      enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.

      In a controlled, open, randomized experiment, eight healthy, overweight men will be studied
      on an intervention day, where they receive acipimox, and on a control day. The study day
      includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a
      biopsy from adipose tissue.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 20, 2017</completion_date>
  <primary_completion_date type="Actual">January 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of GLP-1 in plasma</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity by measuring blood glucose after an OGTT</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin secretion by measuring levels of insulin and c-peptid</measure>
    <time_frame>9 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma</measure>
    <time_frame>9 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of acipimox 250 mg p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>P.o. administration of 250 mg acipimox</description>
    <arm_group_label>Acipimox</arm_group_label>
    <other_name>Olbetam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men

          -  Healthy

          -  BMI 25-35

        Exclusion Criteria:

          -  Known DM2

          -  Receiving hypolipidemic drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Otto L JÃ¸rgensen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Pais R, Gribble FM, Reimann F. Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab. 2016 Feb;7(1):24-42. doi: 10.1177/2042018815618177. Review.</citation>
    <PMID>26885360</PMID>
  </reference>
  <reference>
    <citation>Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753-67. doi: 10.1586/14779072.2015.1054810. Review.</citation>
    <PMID>26106933</PMID>
  </reference>
  <reference>
    <citation>Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3.</citation>
    <PMID>12563315</PMID>
  </reference>
  <reference>
    <citation>Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014 Jan;25(1):42-52. doi: 10.1016/j.tem.2013.09.002. Epub 2013 Oct 18. Review.</citation>
    <PMID>24140022</PMID>
  </reference>
  <reference>
    <citation>Fulcher GR, Walker M, Catalano C, Farrer M, Alberti KG. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox. Clin Sci (Lond). 1992 May;82(5):565-71.</citation>
    <PMID>1317767</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acipimox</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

